ToGA
The trial that brought the breast-cancer drug Herceptin to stomach cancer, the first targeted therapy to improve survival in this disease.
OS 13.8 vs 11.1 months (HR 0.74; Lancet 2010); 16.0 months in IHC3+ or IHC2+/FISH+ tumours. Established HER2 testing for all advanced gastric cancers and the trastuzumab-chemotherapy backbone that KEYNOTE-811 (pembrolizumab added) and HERIZON-GEA-01 (zanidatamab) have since built on.
- Median 13.8 vs 11.1 months with Trastuzumab + chemotherapy compared with Chemotherapy; about 2.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 26 percent lower chance of the event at any given time (hazard ratio 0.74, likely range 0.6 to 0.91).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: First-line HER2-positive advanced gastric/GEJ adenocarcinoma: trastuzumab + cisplatin/fluoropyrimidine vs chemotherapy. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
594 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Trastuzumab + chemotherapy | 294 | 13.8 months | 0.74 (0.6–0.91) | — | link |
| Chemotherapy | 290 | 11.1 months |
Pages like this
not linked directly; found by shared links- TrialDESTINY-Gastric04
Shares HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd, Kohei Shitara, HER2, Oesophageal cancer.
- TrialHERIZON-GEA-01
Shares HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd, Trastuzumab, HER2, Oesophageal cancer.
- PersonYelena Y. Janjigian
Shares Trastuzumab, HER2, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- Key paperSPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer
Shares Yung-Jue Bang, Kohei Shitara, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- ProductZanidatamab
Shares HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd, HER2, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TermSiewert classification (GEJ tumours)
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- InstitutionHenan Cancer Hospital
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
- TrialMOUNTAINEER & MOUNTAINEER-03
Shares Trastuzumab, HER2.